Skip to main content
Premium Trial:

Request an Annual Quote

Grail Raises $900M in Series B Round

NEW YORK (GenomeWeb) – Grail has raised $900 million out of a planned $1 billion, in the first close a Series B financing round that was led by Arch Venture Partners and included Johnson and Johnson Innovation as well as Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. 

Grail plans to use the financing to support ongoing efforts in product development and the validation of its tests for early-stage cancer detection, including its Circulating Cell-free Genome Atlas study and other large-scale clinical trials.

The firm said that some of the proceeds were also used to repurchase part of Illumina's stake in the company. Illumina now owns "slightly less than 20 percent" of Grail.

The company announced its intention in January to raise $1 billion in the Series B round before the end of the first quarter.

Grail CEO Jeff Huber said in a statement that Grail "made tremendous progress in 2016" toward its goal of developing a noninvasive test for early cancer detection. It will continue to leverage "high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science," he said.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.